ArticleIJTLD open2026
Pharmacodynamic evidence for tedizolid use in
Article in IJTLD open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Novel regimens for treatment ofbioRxiv : the preprint server for biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
objectiveOn guideline-based therapy for
designWe performed a 28-day study in the HFS-MAC inoculated with five different MAC isolates treated with six daily exposures, using intrapulmonary pharmacokinetics of tedizolid. Data were analysed using inhibitory sigmoid maximal effect (
resultsTedizolid killed the five clinical isolates of MAC with an
conclusionBased on the reported HFS-MAC studies using multiple clinical isolates of MAC, we propose that tedizolid at 200-300 mg/day should be tested as the backbone of novel combinations to treat MAC-LD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.